Lannett Company, Inc. (AMEX:LCI)
The Company develops, manufactures, markets and distributes generic versions of pharmaceutical products.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
FDA approvals opened up after 483's were fixed.
Backlog of approvals to come
Cody labs starting to hit stride and provide profits.
Recs
Looks like morphine sulfate is the rage.
Recs
LCI seems to have plans for new products and marketing they look as if they will do well over the next few months holding their own while the market makes the necessasry corrections.
Recs
The stock has been on the rise as of late and is doing so on the back of solid financials. The company in the past five years has had a top out in the low twenties with similiar data to what it is displaying currently. 200% increase within the next 1-2 years.
Recs
Correction only
Recs
Whoever said this stock is under valued needs to learn what value really is. LCI has a PE ratio over 100. The stock trades within 10% of its 52 week high. Returns on assets, equity, and capital is almost nothing. No dividend. Less than 2% profit margin is weak. This is not value.
I want to see this stock drop down to $3 per share before I close this out.
Recs
Insider buys
Recs
Company has great financials and shows undervaluation. Additionally, generic pharmaceuticals are becoming a bigger and bigger trend.
Recs
Great business in a growth industry. Fundamentals look real solid.
Recs
New facilities, managment team refocused, many applications awaiting approval.
Recs
Seems underpriced given earnings projected by the lone analyst. Haven't had time to really dig into it though.
Recs
beaten, high value, lhigh growth, low price, rebounding
Recs
will triple! on the verge of breakthrough!
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 13 of 13